AEGiS-14IAC: Benefit effects of capsular pneumococcal polysaccharides immunization on hiv type 1 and type 2 infected individuals in Senegal.

14th International AIDS Conference


Barcelona, Spain - July 7-12, 2002

DonateNow
Print this article

Benefit effects of capsular pneumococcal polysaccharides immunization on hiv type 1 and type 2 infected individuals in Senegal.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. B10201)

Dieye TN, Sow PS, Simonart T, Gueye A, Delforge ML, Popper SJ, Crusiaux A, Devleeschouwer M, Diakhate L, Kanki P, Mboup S, Farber CM
Immunodeficiency unit, Erasme university hospital, ULB, Brussels, Belgium

OBJECTIVE: Comparative evaluation of plasma HIV-RNA levels, humoral and cellular responses on HIV-1 and HIV-2 individuals after immunization with non T dependent 23 valent pneumococcal polysaccharides antigens (PPS).

METHODS: 12 HIV-1, 9 HIV-2 and 8 HIV negative subjects received PPS. Blood was collected on day 0, 7 and 30. HIV-1 and HIV-2 RNA and PPS-IgG antibody were evaluated. CD4 cell counts, activation, memory and maturation markers of T lymphocyte subsets were determined. Proliferative T test to pokeweed mitogen (PWM) were performed.

RESULTS: CD4 counts, memory CD45RO, naïve CD45RA, CD69 and HLA-DR did not vary significantly. Proliferative response to PWM was present but low in HIV-1 and in HIV-2 infected subjects as compared to HIV-negative controls. A significant rise in PPS-IgG was demonstrated at day 30 after immunization (p<0.027; p<0.036; p<0.036) respectively in HIV-1, HIV-2 and control subjects. Anti PPS-IgG showed a two fold increase in the specific immune response at day 30, in 40% of HIV-1, 75% of HIV-2 and 87.5% of controls subjects. HIV-1 and HIV-2 RNA copies were stable in all of patients. Any pneumoccocal infection was observed eighteen months after vaccination.

CONCLUSION: Our results showed a significant but suboptimal and protective immune response to PPS, a non T dependent antigen, in HIV-1, HIV-2 patients and control subjects. PPS was more immunogenic in HIV-2 than in HIV-1-infected subjects. Evaluation of vaccine efficacy may be compromise by limited responses to common vaccine serotypes. Our results showed benefit effects of non T dependent capsular pneumococcal polysaccharide antigens on HIV patients.

Keywords: AEGIS, HIV-1, HIV, HIV Infections, Vaccination, Streptococcus pneumoniae, HIV-2, HIV Seropositivity, CD4 Lymphocyte Count, HIV Antibodies, Polysaccharides, Bacterial Capsules, Senegal, Human, immunologyKWDaegis,hiv-1,hiv,hivinfections,vaccination,streptococcuspneumoniae,hiv-2,hivseropositivity,cd4lymphocytecount,hivantibodies,polysaccharides,bacterialcapsules,senegal,human,immunology

020707
B10201

Copyright © 2002 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.